Baclofen

Fleqsuvy, Ozobax DS and Lyvispah labels describe spasticity due to multiple sclerosis, including flexor spasms, associated pain, clonus and rigidity, and possible benefit in spinal-cord injury/disease. They are not indicated for skeletal muscle spasm from rheumatic disorders. Do not equate this with an unrestricted indication for ordinary acute back pain.

Lioresal Intrathecal treats severe spasticity after a positive intrathecal screening response. For spinal-cord-origin spasticity, chronic infusion is reserved for inadequate oral response or intolerable CNS effects at effective oral doses. Following traumatic brain injury, the label specifies waiting at least 1 year before considering long-term infusion. An approved compatible pump and trained team are required.

This profile verifies two oral liquids and Lioresal Intrathecal; tablet/other injection brands need their own package/device instructions. Lyvispah granule labeling is described separately: Amneal discontinued distribution/promotion June 30,2025, with pharmacy availability limited to residual stock. A retained DailyMed label is not proof of current commercial supply.

The liquid labels suggest the following gradual regimen, adjusted to response/tolerability, with a maximum 80 mg/day (20 mg four times daily). These are not automatic increases for every patient, especially with organ impairment. Prescriptions should include both mg and the correct product-specific mL.

Shake Fleqsuvy well and use a calibrated oral/enteral syringe, not a household spoon. Its NG administration instructions apply to tubes 8 French or larger with specified flushes; this profile does not substitute a generic tube procedure. Ozobax DS is a 2 mg/mL solution; do not assume an older 1 mg/mL solution has the same mL dose. Lyvispah, if residual stock is prescribed, uses whole packets that dissolve in the mouth or are given via its labeled food/tube procedure.

Use the 50 mcg/mL screening product: usual initial bolus 50 mcg (1 mL), administered over at least 1 minute, followed by 4–8 hours observation. If inadequate, the label allows 75 mcg then 100 mcg on subsequent trials 24 hours apart. Very small pediatric patients may first receive 25 mcg. Lack of response to 100 mcg excludes candidacy for chronic pump infusion. Resuscitation-capable monitoring is required.

After implantation, the initial 24-hour dose is twice the effective screening dose, unless its effect lasted more than 8 hours, in which case use that screening dose over 24 hours. No increase in the first 24 hours. Thereafter adult spinal-origin increments are 10–30% no more than once per 24 hours; cerebral-origin/pediatric increments 5–15% no more than once per 24 hours, under close monitoring.

Chronic dosing is individualized to benefit, useful tone and adverse effects. The label reports most adult spinal-origin patients maintained at 300–800 mcg/day, with limited experience above 1,000 mcg/day; most cerebral-origin patients at 90–703 mcg/day. These are observed ranges, not mandatory targets or universal maxima. At refills, labeled increases are up to 40% for spinal origin and 20% for cerebral origin; pediatric maintenance follows cerebral-origin recommendations. Sudden escalation need may indicate catheter malfunction.

Renal impairment can require dose reduction; the reviewed labels supply no validated CrCl adjustment table. Older patients generally start cautiously. No formal hepatic adjustment regimen is provided. Reduce oral therapy slowly; pump interruption/withdrawal requires urgent specialist management, not an improvised oral bridge.

Hypersensitivity to baclofen is contraindicated. Lioresal Intrathecal is only for intrathecal administration; its label excludes IV, IM, subcutaneous and epidural administration. Oral liquids must never enter a pump. Pump refill-port errors can cause fatal overdose even when the concentration is correct.

Lioresal Intrathecal has a boxed warning for potentially fatal abrupt withdrawal and requires careful pump programming, monitoring, refill scheduling, alarm recognition and caregiver education. The reviewed oral liquids/granules do not have an FDA box, but have serious withdrawal warnings; absence of a box does not justify abrupt oral cessation.

Oral treatment commonly causes drowsiness, dizziness, weakness and nausea, with possible hypotension, confusion, constipation or urinary effects. Intrathecal effects include hypotonia, somnolence, dizziness, nausea and urinary retention; severe respiratory/CV depression, seizure, infection/device complications and withdrawal are important. Trial frequencies from different routes/populations are not directly comparable.

Alcohol, opioids, benzodiazepines and other sedating medicines can add to baclofen’s CNS depression. Review the full list and monitor sedation/respiration; a stable baclofen dose can become unsafe after another medicine is added. Avoid self-directed sedative combinations.

Systematic intrathecal interaction experience is limited. The label reports hypotension/dyspnea with epidural morphine. Intrathecal analgesic admixtures have been associated with catheter-tip mass reports; do not infer compatibility or add medicines to the baclofen reservoir without validated product/device instructions.

When a pump is initiated, concomitant oral antispastic medicines may need gradual reduction to avoid toxicity. Abruptly reducing them can cause withdrawal. Oral/enteral baclofen alone cannot be relied upon to stop progression of intrathecal withdrawal; emergency restoration and supportive treatment need a specialist team.

The reviewed oral-product labels do not establish safety/effectiveness below age 12. Lioresal Intrathecal does not establish safety/effectiveness below age 4; children also need sufficient body size for the selected pump. Very-small-child screening differs from ordinary screening. Older patients need cautious oral selection and renal-function assessment.

Baclofen is largely excreted unchanged by kidneys; impaired renal function can increase exposure and require lower dosing/close assessment. Intrathecal labeling also advises renal caution despite lower plasma exposure. No reviewed source establishes a universal renal formula, dialysis dosing schedule or hepatic adjustment table.

Human developmental-risk data are limited and animal adverse findings exist. Oral labels report neonatal withdrawal and direct a clinician-supervised gradual reduction/discontinuation before delivery when continued in pregnancy; do not self-stop or apply that oral instruction automatically to a pump. Intrathecal use requires individualized benefit-risk assessment while protecting against maternal pump withdrawal.

Oral baclofen enters milk; infant effects are incompletely characterized and withdrawal can occur when maternal treatment or breastfeeding stops. Consider maternal need, infant risks and breastfeeding benefits together. Intrathecal label states milk levels are unknown and requires benefit-risk assessment; low maternal plasma exposure is not proof of absent infant exposure.

The precise therapeutic mechanism is incompletely established; baclofen is thought to act through GABA-B pathways and inhibition of mono-/polysynaptic spinal reflexes. CNS depression accompanies its antispastic effect and can include respiratory/CV suppression.

Fleqsuvy fasted-study peak occurred around 1 hour with an apparent half-life about 5.6 hours; renal unchanged-drug excretion and variability matter clinically. Ozobax DS’s current PK section reports a study of 5 mg/5 mL solution, not the currently marketed 2 mg/mL DS strength; its approximately 0.75-hour peak/5.7-hour half-life should not be mislabeled as a direct DS-formulation study.

Intrathecal bolus data report average CSF elimination half-life about 1.5 hours and clearance around 30 mL/hour. Continuous-infusion plasma concentrations are expected to be low, with a variable lumbar-to-cisternal gradient. These small-study values do not predict individual pump dose, refill interval or safe time after an interruption.

Assess function, spasticity, strength/balance, sedation, renal risk, seizure control and interacting medicines. Verify mg/mL and measuring device at each refill/formulation change. Read product patient instructions, avoid hazardous activity until effects are known, and discuss pregnancy/breastfeeding and taper plans.

Keep refill appointments, recognize alarms and carry the pump treatment/contact information. Return of spasticity, itching/tingling, unexplained escalating dose needs, pain or new neurologic deficits warrants prompt evaluation of delivery/catheter problems. Refills/programming/concentration changes are performed by trained personnel using strict aseptic technique and the actual device manual.

Marked drowsiness, hypotonia, slow breathing or coma may signal overdose; fever, severe rebound rigidity or confusion may signal withdrawal. Both require immediate medical assessment. There is no specific baclofen antidote. Do not attempt a home pump refill, port injection or oral replacement calculation.

Fleqsuvy 25 mg/5 mL (5 mg/mL) is an orange/yellow grape-flavored suspension; 120 mL NDC 52652-6001-1. Ozobax DS 10 mg/5 mL (2 mg/mL) is a clear colorless solution; 237 mL NDC 69528-302-08. Lioresal’s 50 mcg/mL screening ampule is 1 mL, supplied in screening kits (NDC 70121-2496-5). Verify the actual package/device.

Reviewed oral liquids are 5 mg/mL suspension and 2 mg/mL solution. Lyvispah 5/10/20 mg oral granules are availability-qualified residual-stock forms. Lioresal Intrathecal concentrations are 50, 500 and 2,000 mcg/mL: screening 50 mcg/1 mL, maintenance 10 mg/20 mL, 10 mg/5 mL or 40 mg/20 mL. These preservative-free injections are not oral products or general IV formulations.

Fleqsuvy and Ozobax DS: 20–25°C with 15–30°C excursions; Fleqsuvy discard 2 months after first opening. DS uses a tight light-resistant child-resistant container; its reviewed label supplies no matching 2-month discard rule. Lyvispah packets use controlled room temperature. Lioresal needs no refrigeration: do not store above 30°C, freeze, heat-sterilize or autoclave; single-use ampules, discard residual contents. Dilution requires sterile preservative-free saline and device-specific professional instructions.